A phase II, open label, uncontrolled, multi center study to evaluate safety and immunogenicity of a commercially available surface antigen, inactivated, (adjuvanted with MF59C.1) influenza vaccine, formulation 2006-2007, when administered to elderly subjects
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary) ; MF 59
 - Indications Influenza virus infections
 - Focus Pharmacodynamics
 - Sponsors Novartis
 
Most Recent Events
- 04 Jul 2007 New trial record.